We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+35.2%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.01B
AUM Growth
+$314M
Cap. Flow
+$143M
Cap. Flow %
14.12%
Top 10 Hldgs %
64.85%
Holding
53
New
6
Increased
8
Reduced
14
Closed
16

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$111M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$50M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$19.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$18.9M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.8M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$14.7M
2
BLUE
bluebird bio
BLUE
+$14.3M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M
4
ARDX icon
Ardelyx
ARDX
+$9.17M
5
TXMD icon
TherapeuticsMD
TXMD
+$8.9M

Sector Composition

Rank Sector Weight
1 Healthcare 84.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRA
26
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$9.1M 0.9%
15,125
– –
NTRA icon
27
Natera
NTRA
$36.4B
$8.46M 0.84%
783,520
-1
-0% -$10
TENX icon
28
Tenax Therapeutics
TENX
$393M
$7.84M 0.78%
75
-8
-10% -$830K
VTAE
29
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$5.81M 0.58%
321,161
– –
ZYNE
30
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.11M 0.51%
507,191
-17,809
-3% -$236K
AGTC
31
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.82M 0.48%
236,059
+114,959
+95% +$1.77M
ALPN
32
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.74M 0.47%
153,216
– –
AKTX
33
Akari Therapeutics
AKTX
$14.4M
$3.83M 0.38%
330
– –
ORKA
34
Oruka Therapeutics
ORKA
$5.31B
$3.62M 0.36%
3,603
-153
-4% -$173K
DSCI
35
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.93M 0.29%
+641,236
New +$3.04M
NDRM
36
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.47M 0.24%
144,671
-280,329
-66% -$5.46M
ARMP icon
37
Armata Pharmaceuticals
ARMP
$168M
$213K 0.02%
383
-82
-18% -$62.8K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-63,026
Closed -$5.07M
BLUE
39
DELISTED
bluebird bio
BLUE
– –
-12,921
Closed -$14.3M
BNTC icon
40
Benitec Biopharma
BNTC
$414M
– –
-551
Closed -$864K
DRRX
41
DELISTED
DURECT Corp
DRRX
– –
-38,180
Closed -$745K
MCRB icon
42
Seres Therapeutics
MCRB
$45M
– –
-12,332
Closed -$7.31M
NVAX icon
43
Novavax
NVAX
$1.21B
– –
-8,103
Closed -$1.15M
RARE icon
44
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-56,067
Closed -$5.4M
TXMD icon
45
TherapeuticsMD
TXMD
$23.8M
– –
-30,369
Closed -$8.9M
XNCR icon
46
Xencor
XNCR
$1.45B
– –
-679,885
Closed -$8.31M
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-314,349
Closed -$12.6M
FRTX
48
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-662
Closed -$958K
CYTO
49
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-6
Closed -$1.67M
BLCM
50
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-31,570
Closed -$4.59M
1
2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, RA Capital Management held 53 positions worth $1.01B, up 45% from $696M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management deployed $143M of net new capital in Q4 2015, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Wave Life Sciences: 7,088,651 shares worth $113M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $14.7M trimmed.

  • RA Capital Management's largest Q4 2015 buy was Wave Life Sciences: 7,088,651 shares worth $113M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q4 2015, an estimated $18.9M increase.
  • RA Capital Management's biggest Q4 2015 reduction was Collegium Pharmaceutical, cutting an estimated $14.7M.
  • RA Capital Management fully exited bluebird bio in Q4 2015, selling an estimated $14.3M.
  • RA Capital Management's ten largest holdings make up 65% of its $1.01B portfolio in Q4 2015.
  • RA Capital Management opened 6 new positions and closed 16 in Q4 2015.
  • RA Capital Management's portfolio value rose 45% quarter-over-quarter to $1.01B.

Based on RA Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.